C25006 Ph4 of Brentuximab Vedotin in Patients with Large Cell Lymphoma

• Research type

  Research Study

• Full title

  A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

• IRAS ID

  124893

• Contact name

  John Radford

• Contact email

  john.radford@manchester.ac.uk

• Sponsor organisation

  Takeda Development Center Americas Inc

• Eudract number

  2012-004128-39

• REC name

  HSC REC A

• REC reference

  13/NI/0072

• Date of REC Opinion

  8 Jul 2013

• REC opinion

  Further Information Favourable Opinion